Back to Search
Start Over
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA
- Source :
- Annals of Oncology, Annals of Oncology, Oxford University Press (OUP), 2013, 24 (10), pp.2612-8. 〈10.1093/annonc/mdt282〉, Annals of Oncology, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩, Annals of Oncology, Elsevier, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩
- Publication Year :
- 2013
- Publisher :
- HAL CCSD, 2013.
-
Abstract
- International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for the 227 patients with non-Hodgkin Lymphoma (NHL), with a significant difference between aggressive and indolent NHL (5.2 months versus 19.4 months, respectively). We further analyzed 166 NHL patients for whom detailed characteristics were available. Among these patients, 63.5% received a treatment, either local (7.5%) or systemic (56%). Lymphoma was reported as the main cause of death (40%). Treatment administration was associated with improved OS in patients with aggressive (P < 0.001) but not indolent NHL (P = 0.96). In patients with aggressive NHL, hypoalbuminemia appeared as a strong and independent negative prognostic factor. CONCLUSIONS: The median OS is short in 90+ patients diagnosed with lymphoma but some patients experience prolonged survival. Lymphoma represents the main cause of death in these patients. Treatment may improve survival of selected patients with aggressive but not indolent NHL. Management of these patients may be guided by prognostic factors identified in this study, notably serum albumin.
- Subjects :
- Male
medicine.medical_specialty
Palliative care
Survival
Population
[SDV.CAN]Life Sciences [q-bio]/Cancer
lymphoma
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
immune system diseases
Internal medicine
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Hypoalbuminemia
education
Serum Albumin
030304 developmental biology
Cause of death
Retrospective Studies
Aged, 80 and over
0303 health sciences
education.field_of_study
palliative care
business.industry
Incidence (epidemiology)
Incidence
Lymphoma, Non-Hodgkin
Hematology
medicine.disease
Prognosis
Comorbidity
3. Good health
Lymphoma
Surgery
aged 80 and over
comorbidity
Oncology
030220 oncology & carcinogenesis
Female
Lymphoma, Large B-Cell, Diffuse
business
Diffuse large B-cell lymphoma
Subjects
Details
- Language :
- English
- ISSN :
- 09237534 and 15698041
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology, Annals of Oncology, Oxford University Press (OUP), 2013, 24 (10), pp.2612-8. 〈10.1093/annonc/mdt282〉, Annals of Oncology, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩, Annals of Oncology, Elsevier, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩
- Accession number :
- edsair.doi.dedup.....5e4088556bb300b9d60ee3dccc46e9e4